Publications by authors named "K Mauss"
Sepsis is a life-threatening condition caused by the body's overwhelming response to an infection, such as pneumonia or urinary tract infection. It occurs when the immune system releases cytokines into the bloodstream, triggering widespread inflammation. If not treated, it can lead to organ failure and death.
View Article and Find Full Text PDF[Retrospective Evaluation of the Use of a Dermal Substitute in Septorhinoplasty].
Handchir Mikrochir Plast Chir
August 2023
Background: At the present time, various methods exist for camouflaging the dorsum of the nose in septorhinoplasty. The subject of this paper is a retrospective descriptive evaluation of the surgical use of the bovine collagen/glycosaminoglycan matrix Integra Dermal Regeneration Template Single Layer Thin (IDRT-SL Thin) developed by Integra LifeSciences in septorhinoplasty procedures.
Methodology: The focus of this work is to evaluate the postoperative tolerability, the safety, and the course of wound healing when IDRT-SL Thin is applied as a collagen sheet in septorhinoplasty.
Article Synopsis
- Aspidasept (Pep19-2.5) and its derivative, Pep19-4LF (Aspidasept II), are synthetic polypeptides designed to combat moderate to severe bacterial infections and associated systemic inflammation, like sepsis.
- The study examined the toxic behavior of these peptides in various cell models and electrophysiological experiments, particularly focusing on their effects on the hERG channel, which is critical for heart health.
- Findings from mouse and rat models have helped establish a therapeutic window for the safe use of Aspidasept, paving the way for potential clinical applications.
The polypeptide Pep19-2.5 (Aspidasept) has been described to act efficiently against infection-inducing bacteria by binding and neutralizing their most potent toxins, i.e.
View Article and Find Full Text PDFAn update on endotoxin neutralization strategies in Gram-negative bacterial infections.
Expert Rev Anti Infect Ther
April 2021
Introduction: Gram-negative bacterial infections represent still a severe problem of human health care, regarding the increase in multi-resistance against classical antibiotics and the lack of newly developed antimicrobials. For the fight against these germs, anti-infective agents must overcome and/or bind to the Gram-negative outer membrane consisting of a lipopolysaccharide (LPS, endotoxin) outer leaflet and an inner leaflet from phospholipids, with additional peripheral or integral membrane proteins (OMP's).
Areas Covered: The current article reviews data of existing therapeutic options and summarizes newer approaches for targeting and neutralizing endotoxins, ranging from in vitro over in vivo animal data to clinical applications by using databases such as Medline.